FDA gives Dacogen orphan drug status
MGI Pharma announced that the FDA had given orphan drug status to Dacogen as a therapy for leukemia. Dacogen is currently in late-stage trials for leukemia and was approved for bone marrow disorders in May. European regulators have given Dacogen orphan drug status for Myelodysplastic Syndromes and leukemia. Orphan drug status provides seven years of market exclusivity for a drug aimed at a small group of patients.
- read the AP report on Dacogen
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets